Related Experiment Video
Updated: May 31, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal
Hironori Satoh1, Akira Inoue, Kunihiko Kobayashi
1Tohoku University Hospital, Sendai, Japan.
Introduction:
Although standard schedule of gefitinib was the administration of 250 mg tablet every day, many patients need dose reduction because of toxicities. However, the efficacy of such low-dose gefitinib for patients with epidermal growth factor receptor-mutated non-small cell lung cancer has rarely been evaluated.
Methods:
A post hoc comparison of the efficacy (response rate and survival) in patients treated with gefitinib with or without any dose reduction in NEJ002 study was performed.
Results:
Among 114 patients treated with first-line gefitinib in NEJ002, 61 (54%) continued gefitinib without any dose reduction until their diseases progressed, and 53 (46%) reduced their dose of gefitinib because of some toxicities. There was no significant difference of patient characteristics between the two groups. The progression-free survival of low-dose group tended to be better than that of standard-dose group (median progression-free survival, 11.8 versus 9.9 months; p = 0.144), and the overall survival of low-dose group was also better than that of standard-dose group (median survival time, 32.7 versus 25.3 months; p = 0.049).
Conclusions:
The results suggest that low-dose gefitinib may be clinically not inferior to standard-dose gefitinib for non-small cell lung cancer with sensitive epidermal growth factor receptor mutations. Prospective study of low-dose gefitinib is warranted especially for frail patients who need less toxic treatment.
Insights
Lowering the dose of gefitinib (a targeted therapy) may be as effective as the standard dose for non-small cell lung cancer patients with EGFR mutations. This dose reduction can help manage toxicities while maintaining treatment efficacy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Standard gefitinib dosing (250 mg daily) often requires reduction due to toxicity.
- Limited data exists on the efficacy of reduced-dose gefitinib in EGFR-mutated NSCLC.
Purpose of the Study:
- To compare the efficacy of standard-dose versus reduced-dose gefitinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Main Methods:
- A post hoc analysis of the NEJ002 study was conducted.
- Efficacy was assessed by response rate and survival in patients who received gefitinib with or without dose reduction.
Main Results:
- Of 114 patients, 53 (46%) required dose reduction.
- Progression-free survival (11.8 vs. 9.9 months) and overall survival (32.7 vs. 25.3 months) were numerically better in the low-dose group.
- Overall survival showed a statistically significant improvement in the low-dose group (p=0.049).
Conclusions:
- Low-dose gefitinib appears clinically non-inferior to standard-dose gefitinib for EGFR-mutated NSCLC.
- Further prospective studies are recommended for low-dose gefitinib, particularly in frail patients needing less toxic options.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...